Suchergebnisse - "O'Connor, Owen A"

PubPharm (3)

1

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma : an open-label, phase 1, dose-escalation, first-in-human study

enthalten in: The Lancet. Oncology | 2018

von Burris, H. | Flinn, I. | Patel, M. | +12

CommentIn: Lancet Oncol. 2018 Apr;19(4):432-434. - PMID 29475725

2

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma : an international, multicentre, single-arm, phase 1-2 trial

enthalten in: The Lancet. Oncology | 2018

von O'Connor, O. | Lue, J. | Sawas, A. | +19

CommentIn: Lancet Oncol. 2018 Feb;19(2):162-163. - PMID 29276023

3

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies : a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

enthalten in: The Lancet. Oncology | 2010

von Wilson, W. | O'Connor, O. | Czuczman, M. | +14

1
[1]